Literature DB >> 3734781

Dihydrotetrabenazine binding and monoamine uptake in mouse brain regions.

D Scherman.   

Abstract

Binding of [2-3H]dihydrotetrabenazine and uptake of 5-hydroxytryptamine (serotonin) were studied in mouse brain cerebellum, pons-medulla, frontal cortex, hypothalamus, hippocampus, and striatum. Binding of [2-3H]dihydrotetrabenazine to homogenates of these brain areas is stable for several hours and occurs at a homogeneous class of binding sites (KD = 2.4 nM). Subcellular fractionation and regional distribution of [2-3H]dihydrotetrabenazine binding and serotonin uptake showed that the ligand binds to synaptic vesicles. Dihydrotetrabenazine inhibited serotonin uptake with the same inhibitory constant (IC50 = 2.6 nM) for synaptic vesicles from brain regions containing 3,4-dihydroxyphenylethylamine (dopamine) or serotonin and noradrenaline in different proportions. This constant is similar to the KD of [2-3H]dihydrotetrabenazine, which suggests that the latter ligand labels specifically and with the same affinity the monoamine transporter from various monoaminergic synaptic vesicles. Therefore the regional differences in central monoamine depletion induced in vivo by tetrabenazine are not due to regional differences in inhibition of vesicular monoamine uptake. Moreover, vesicular monoamine transporters from the central and peripheral nervous systems of various mammals and from bovine adrenal glands have comparable affinity for substrate and inhibitor (Km values for serotonin and IC50 for dihydrotetrabenazine are about 0.8 microM and 3 nM, respectively) and comparable turnover number (10-35 molecules transported per transporter per minute), which suggests the involvement of a common transporter molecule in the process of monoamine uptake by the various monoaminergic storage vesicles.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734781     DOI: 10.1111/j.1471-4159.1986.tb04506.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

Authors:  N Takahashi; L L Miner; I Sora; H Ujike; R S Revay; V Kostic; V Jackson-Lewis; S Przedborski; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

3.  The effect of psychostimulants on [3H]dopamine uptake and release in rat brain synaptic vesicles.

Authors:  K Schwartz; A Weizman; M Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

4.  Visualizing pancreatic beta-cell mass with [11C]DTBZ.

Authors:  Norman Ray Simpson; Fabiola Souza; Piotr Witkowski; Antonella Maffei; Anthony Raffo; Alan Herron; Michael Kilbourn; Agata Jurewicz; Kevan Herold; Eric Liu; Mark Adam Hardy; Ronald Van Heertum; Paul Emerson Harris
Journal:  Nucl Med Biol       Date:  2006-10       Impact factor: 2.408

5.  The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.

Authors:  J M Wilson; S J Kish
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

6.  A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles.

Authors:  Etienne A Cartier; Leonardo A Parra; Tracy B Baust; Marisol Quiroz; Gloria Salazar; Victor Faundez; Loreto Egaña; Gonzalo E Torres
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

7.  Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.

Authors:  Anthony Raffo; Kolbe Hancock; Teresa Polito; Yuli Xie; Gordon Andan; Piotr Witkowski; Mark Hardy; Pasquale Barba; Caterina Ferrara; Antonella Maffei; Matthew Freeby; Robin Goland; Rudolph L Leibel; Ian R Sweet; Paul E Harris
Journal:  J Endocrinol       Date:  2008-07       Impact factor: 4.286

8.  Releasing activities of d-fenfluramine and fluoxetine on rat hippocampal synaptosomes preloaded with [3H]serotonin.

Authors:  M Gobbi; E Frittoli; T Mennini; S Garattini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-01       Impact factor: 3.000

9.  Anorectic effect and brain concentrations of D-fenfluramine in the marmoset: relationship to the in vivo and in vitro effects on serotonergic mechanisms.

Authors:  S Caccia; M Anelli; C Fracasso; E Frittoli; P Giorcelli; M Gobbi; C Taddei; S Garattini; T Mennini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-03       Impact factor: 3.000

10.  Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model.

Authors:  Fabiola Souza; Norman Simpson; Anthony Raffo; Chitra Saxena; Antonella Maffei; Mark Hardy; Michael Kilbourn; Robin Goland; Rudolph Leibel; J John Mann; Ronald Van Heertum; Paul E Harris
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.